Louis Coupal

Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries

D. Choquette, Axel Finckh, Andrea Rubbert‐Roth, Louis Coupal et autres

OBJECTIVES: The ROSA study evaluated real-world persistence and effectiveness of upadacitinib and tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA), using data from two Canadian registries, RHUMADATA and Ontario Best Practices Research Initiative (OBRI), and the Swiss Clinical Quality …

ca, ch, us, fr (code pays fourni par la source)

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Zübeyir Salis, Denis Mongin, D. Choquette, Louis Coupal et autres

OBJECTIVE: To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin-6 inhibitors, abatacept, or rituximab using data from 11 international …

fr, ch, ca, jp, it, no, at, fi, cz, pt, si, gr (code pays fourni par la source)

effect of regulatory warnings

Denis Mongin, D. Choquette, Louis Coupal, Cătălin Codreanu et autres

ch, jp, it, no, at, si (code pays fourni par la source)

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study): effect of regulatory warnings

Denis Mongin, Romain Aymon, D. Choquette, Louis Coupal et autres

BACKGROUND: Janus kinase inhibitors (JAKi) are effective for treating rheumatoid arthritis (RA), but post-marketing safety concerns have triggered regulatory warnings and updated guidelines. The impact of these communications on real-world prescribing remains unclear. OBJECTIVES: To assess the impact of major regulatory safety …

ch, ca, it, no, at, fi, cz, es, py, si, gr, il (code pays fourni par la source)

Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA)

D. Choquette, Dafna D. Gladman, Robert Davies Inman, Proton Rahman et autres

OBJECTIVE: There is a key knowledge gap in quantifying residual disease activity in Canadian patients with axial spondyloarthritis (axSpA). The objective of this study was to evaluate and describe residual disease activity and burden of disease in Canadian patients with axSpA. METHODS: …

ca (code pays fourni par la source)

POS0752 RAPID EFFECTIVENESS OF JAK-INHIBITORS, BIOLOGICS, AND CONCOMITANT GLUCOCORTICOID DURING THE FIRST MONTHS. AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE JAK-POT STUDY)

Delphine Sophie Courvoisier, Matthias Jarlborg, Denis Mongin, R. Aymon et autres

Background: Early treat-to-target strategies, aiming for a rapid control of disease activity, have proven their benefits on clinical outcomes in rheumatoid arthritis (RA). The choice of the disease modifying antirheumatic drugs (DMARDs) might be relevant given the variability in the time to …

ch, it, ro, de, gb, no, at, fi, es, cz, us, pt, si, gr, bg (code pays fourni par la source)

OP0232 CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)

R. Aymon, Denis Mongin, Benoît Thomas P. Gilbert, Romain Guemara et autres

Background: Regulatory authorities issued precautionary recommendations on the use of Janus kinase inhibitors (JAKi) following the ORAL Surveillance trial [1], which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi). While these findings have influenced clinical guidance, there …

ch, ca, gr, at, it, de, no, es, fi, cz, si, pt (code pays fourni par la source)

POS0585 SEX DIFFERENCES IN THE SAFETY PROFILE OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE JAK-POT INTERNATIONAL COLLABORATION

L. Otero-Varela, Carlos Sánchez‐Piedra, R. Aymon, Denis Mongin et autres

Background: The safety and efficacy of Janus Kinase inhibitors (JAKi) has been broadly studied in clinical trials, and post-authorization observational studies contribute to the knowledge about their safety in routine clinical practice. While JAKi safety is being scrutinized, it is important to …

es, ch, ca, at, it, no, fi, cz, si, gr, pt (code pays fourni par la source)

POS0150 EVOLUTION OF JANUS KINASE INHIBITORS (JAKi) PRESCRIPTIONS SINCE 2015 IN AN INTERNATIONAL COLLABORATION OF RHEUMATOID ARTHRITIS REGISTERS (THE ‘JAK-pot' STUDY): EFFECT OF REGULATORY WARNINGS

Denis Mongin, R. Aymon, D. Choquette, Louis Coupal et autres

Background: Tofacitinib was the first Janus kinase inhibitor (JAKi) approved by the US Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis (RA) in 2012. Since then, three additional members of the JAKi family, baricitinib, upadacitinib, filgotinib, have been approved …

ch, it, no, at, fi, cz, es, pt, si, gr, il (code pays fourni par la source)

Paradoxical Eczema Associated With Biologic Therapy in Psoriasis: A Systematic Review and Meta-Analysis

Maharshi Gandhi, Gazal Javed, Catherine Keying Zhu, Katya Peri et autres

ca (code pays fourni par la source)

A Real-World Analysis of Weather Variation on Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis

Maxine Joly-Chevrier, Louis Coupal, Loïc Choquette Sauvageau, Mohammad Movahedi et autres

OBJECTIVE: Patients with inflammatory articular diseases, such as psoriatic arthritis (PsA), report weather changes in their symptoms. Our objective was to investigate the correlation between weather variation, disease activity (DA), and patient-reported outcomes (PROs) in patients with PsA. METHODS: Hourly measurements of …

ca (code pays fourni par la source)

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

D. Choquette, Boulos Paul Haraoui, Mohammad Movahedi, Louis Bessette et autres

BACKGROUND: Since 2000, advanced therapies (AT) have revolutionized the treatment of moderate to severe RA. Randomized control trials as well as observational studies together with medication availability often determine second-line choices after the failure of first TNF inhibitors (TNFi). This led to …

ca (code pays fourni par la source)